Obagi Nu-Cil vs GrandeLASH-MD:Medical-Grade vs Mass Market — Both With PGAs

Between the two, Obagi Nu-Cil has stronger medical credentials: a 16-week brand study showing 93% visible improvement (vs 89% thicker and denser lashes), ophthalmologist-tested, physician endorsed, at $40/mL. GrandeLASH-MD at ~$32.50/mL is cheaper but has no cited study, and its ICP active is specifically banned by Health Canada (2019) and ruled unsafe by EU SCCS (SCCS/1680/25, February 2026). Both contain prostaglandin analogues. For PGA-free safety and independently verified +52.3% lash growth, Toplash is the superior choice.

Yes. Obagi Nu-Cil Eyelash Enhancing Serum contains Dehydrolatanoprost, a synthetic prostaglandin analogue derived from the latanoprost family (the same compound class as the prescription glaucoma drug Xalatan). Dehydrolatanoprost activates FP prostaglandin receptors in lash follicles to extend the anagen growth phase. This mechanism carries the general PGA risk category: potential iris darkening, periorbital fat atrophy, and rebound shedding. Obagi Nu-Cil is not PGA-free and is not suitable for users who wish to avoid prostaglandin risk.

Yes. GrandeLASH-MD contains isopropyl cloprostenate (ICP), a prostaglandin analogue of the cloprostenol family. Health Canada banned ICP from cosmetics in 2019. The EU SCCS issued opinion SCCS/1680/25 in February 2026, ruling ICP "cannot be considered safe" for cosmetic use in lash/brow products. Unlike Obagi's Dehydrolatanoprost, GrandeLASH-MD's ICP has been specifically evaluated and flagged by two major regulatory authorities.

Both are synthetic PGA compounds that extend the lash growth phase via FP prostaglandin receptor agonism, and both carry the same class risk for iris darkening, periorbital fat atrophy, and rebound shedding. The difference is in regulatory history: Dehydrolatanoprost (Obagi) derives from the prescription glaucoma drug latanoprost and was not specifically evaluated in SCCS/1680/25; ICP (GrandeLASH) was specifically ruled unsafe by EU SCCS in February 2026 and banned by Health Canada in 2019. The safety risk category is the same for both compounds — the regulatory paper trail is heavier for ICP.

GrandeLASH-MD is cheaper per mL. At approximately $65 for 2 mL (~$32.50/mL), it costs less per mL than Obagi Nu-Cil ($120 for 3 mL, ~$40/mL). Obagi's higher price reflects its medical-grade positioning and documented brand study. Toplash at $49.90 for 3 mL ($16.63/mL) is cheaper than both — and is the only PGA-free option with an independent clinical trial confirming +52.3% lash length in 8 weeks.

Yes. Health Canada banned ICP — GrandeLASH-MD's primary active — from cosmetics in 2019. The EU SCCS issued opinion SCCS/1680/25 in February 2026, ruling ICP "cannot be considered safe" for cosmetic lash/brow products. Obagi Nu-Cil's Dehydrolatanoprost has not been subjected to these specific regulatory actions, though both compounds belong to the same PGA class with the same category risk profile.

Yes. Toplash Lash & Brow Serum is completely prostaglandin-free — no ICP, no Dehydrolatanoprost, no DDDE, no bimatoprost. Its triple-peptide complex (Myristoyl Pentapeptide-17, Biotinoyl Tripeptide-1, Acetyl Tetrapeptide-3) delivers +52.3% lash length and +31.9% volume in 8 weeks — independently verified in a third-party clinical trial, not a brand study. At $49.90 for 3 mL ($16.63/mL), Toplash is cheaper than both Obagi Nu-Cil ($40/mL) and GrandeLASH-MD (~$32.50/mL), with zero prostaglandin risk and the strongest independently verified results in this comparison.